Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 14/20 | 0.45 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
| ▸ | MAP2 | P11137 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7916007 | 0.87 | HTR5A (0.41) | HTR5ASLC9A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7908713 | 0.86 | HTR5A (0.41) | HTR5ASLC9A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL16502443 | 0.83 | SLC22A12 (0.56) | SLC22A12 | |
| SCHEMBL10064301 | 0.81 | HTR5A (0.43) | HTR5ASLC9A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7909266 | 0.80 | IRAK4 (0.49) | HTR5ASLC9A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL615319 | 0.79 | HTR5A (0.53) | HTR5ASLC9A1CYP2C9CYP2C19HTR7 | |
| SCHEMBL7920216 | 0.79 | HTR5A (0.47) | HTR5ASLC9A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL16502445 | 0.79 | PLAU (0.47) | CYP3A4SLC22A12 | |
| SCHEMBL16502844 | 0.77 | HTR5A (0.48) | HTR5ASLC9A1HTR7HTR2B | |
| SCHEMBL614952 | 0.77 | HTR5A (0.55) | HTR5ASLC9A1HTR7HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306621-A1 | ACYLGUANIDINE DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2011-12-15 | — | — | US | disclosed |
| US-20110306621-A1 | ACYLGUANIDINE DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2011-12-15 | — | — | US | disclosed |
| WO-2010090304-A1 | ACYLGUANIDINE DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306621-A1 | ACYLGUANIDINE DERIVATIVES | HTR5A, HTR2A, HTR1A | HTR5A 1/4885SLC9A1 1256/4885CYP3A4 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.